Literature DB >> 18467706

Thrombotic microangiopathy associated with humoral rejection of cardiac xenografts from alpha1,3-galactosyltransferase gene-knockout pigs in baboons.

Akira Shimizu1, Yosuke Hisashi, Kenji Kuwaki, Yau-Lin Tseng, Frank J M F Dor, Stuart L Houser, Simon C Robson, Henk-Jan Schuurman, David K C Cooper, David H Sachs, Kazuhiko Yamada, Robert B Colvin.   

Abstract

Heterotopic cardiac xenotransplantation from alpha1,3-galactosyltransferase gene-knockout (GalT-KO) swine to baboons was performed to characterize immunological reaction to the xenograft in the absence of anti-Gal antibody-mediated rejection. Eight baboons received heterotopic cardiac xenografts from GalT-KO porcine donors. All baboons were treated with chronic immunosuppressive therapy. Both histological and immunohistochemical studies were performed on biopsy and graftectomy samples. No hyperacute rejection was observed. Three baboons were euthanized or died 16 to 56 days after transplantation. The other five grafts ceased beating between days 59 and 179 (median, 78 days). All failing grafts exhibited thrombotic microangiopathy (TM) with platelet-rich fibrin thrombi in the microvasculature, myocardial ischemia and necrosis, and focal interstitial hemorrhage. TM developed in parallel with increases in immunoglobulin (IgM and IgG) and complement (C3, C4d, and C5b-9) deposition, as well as with subsequent increases in both TUNEL(+) endothelial cell death and procoagulant activation (increased expression of both tissue factor and von Willebrand factor and decreased expression of CD39). CD3(+) T-cell infiltration occurred in all grafts and weakly correlated with the development of TM. In conclusion, although the use of GalT-KO swine donors prevented hyperacute rejection and prolonged graft survival, slowly progressive humoral rejection--probably associated with non-Gal antibodies to the xenograft--and disordered thromboregulation represent major immunological barriers to long-term xenograft survival.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18467706      PMCID: PMC2408408          DOI: 10.2353/ajpath.2008.070672

Source DB:  PubMed          Journal:  Am J Pathol        ISSN: 0002-9440            Impact factor:   4.307


  39 in total

1.  alpha1,3-Galactosyltransferase gene-knockout pig heart transplantation in baboons with survival approaching 6 months.

Authors:  Yau-Lin Tseng; Kenji Kuwaki; Frank J M F Dor; Akira Shimizu; Stuart Houser; Yosuke Hisashi; Kazuhiko Yamada; Simon C Robson; Michel Awwad; Henk-Jan Schuurman; David H Sachs; David K C Cooper
Journal:  Transplantation       Date:  2005-11-27       Impact factor: 4.939

2.  A histopathologic grading system of hyperacute (humoral, antibody-mediated) cardiac xenograft and allograft rejection.

Authors:  A G Rose; D K Cooper
Journal:  J Heart Lung Transplant       Date:  1996-08       Impact factor: 10.247

Review 3.  The immunological barriers to xenotransplantation.

Authors:  J L Platt
Journal:  Crit Rev Immunol       Date:  1996       Impact factor: 2.214

4.  Acute humoral xenograft rejection: destruction of the microvascular capillary endothelium in pig-to-nonhuman primate renal grafts.

Authors:  A Shimizu; S M Meehan; T Kozlowski; T Sablinski; F L Ierino; D K Cooper; D H Sachs; R B Colvin
Journal:  Lab Invest       Date:  2000-06       Impact factor: 5.662

5.  In situ localization of tissue factor in human atherosclerotic plaques by binding of digoxigenin-labeled factors VIIa and X.

Authors:  S V Thiruvikraman; A Guha; J Roboz; M B Taubman; Y Nemerson; J T Fallon
Journal:  Lab Invest       Date:  1996-10       Impact factor: 5.662

6.  Species differences in the expression of major histocompatibility complex class II antigens on coronary artery endothelium: implications for cell-mediated xenoreactivity.

Authors:  J K Choo; J D Seebach; V Nickeleit; A Shimizu; H Lei; D H Sachs; J C Madsen
Journal:  Transplantation       Date:  1997-11-15       Impact factor: 4.939

Review 7.  Barriers to xenotransplantation.

Authors:  F H Bach; S C Robson; H Winkler; C Ferran; K M Stuhlmeier; C J Wrighton; W W Hancock
Journal:  Nat Med       Date:  1995-09       Impact factor: 53.440

Review 8.  Discordant organ xenotransplantation in primates: world experience and current status.

Authors:  D Lambrigts; D H Sachs; D K Cooper
Journal:  Transplantation       Date:  1998-09-15       Impact factor: 4.939

9.  Loss of ATP diphosphohydrolase activity with endothelial cell activation.

Authors:  S C Robson; E Kaczmarek; J B Siegel; D Candinas; K Koziak; M Millan; W W Hancock; F H Bach
Journal:  J Exp Med       Date:  1997-01-06       Impact factor: 14.307

10.  Complement-mediated regulation of tissue factor activity in endothelium.

Authors:  S Saadi; R A Holzknecht; C P Patte; D M Stern; J L Platt
Journal:  J Exp Med       Date:  1995-12-01       Impact factor: 14.307

View more
  50 in total

1.  Protection of porcine endothelial cells against apoptosis with interleukin-4.

Authors:  Sylvester M Black; Barbara A Benson; Damé Idossa; Gregory M Vercellotti; Agustin P Dalmasso
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

2.  Minimal effect of bortezomib in reducing anti-pig antibodies in human leukocyte antigen-sensitized patients: a pilot study.

Authors:  Hidetaka Hara; Andrew Bentall; Cassandra Long; Jason Fang; Oleg Andreyev; John Lunz; Mohamed Ezzelarab; Kareem M Abu-Elmagd; Ron Shapiro; David Ayares; Mark Stegall; David K C Cooper
Journal:  Xenotransplantation       Date:  2013-09-03       Impact factor: 3.907

Review 3.  Current status of pig heart xenotransplantation.

Authors:  Muhammad M Mohiuddin; Bruno Reichart; Guerard W Byrne; Christopher G A McGregor
Journal:  Int J Surg       Date:  2015-08-28       Impact factor: 6.071

Review 4.  Which anti-platelet therapies might be beneficial in xenotransplantation?

Authors:  Moritz Schmelzle; Peter J Cowan; Simon C Robson
Journal:  Xenotransplantation       Date:  2011 Mar-Apr       Impact factor: 3.907

5.  Xenotransplantation as a model of integrated, multidisciplinary research.

Authors:  Emanuele Cozzi; Erika Bosio; Michela Seveso; Domenico Rubello; Ermanno Ancona
Journal:  Organogenesis       Date:  2009-01       Impact factor: 2.500

6.  Pig-to-baboon heterotopic heart transplantation--exploratory preliminary experience with pigs transgenic for human thrombomodulin and comparison of three costimulation blockade-based regimens.

Authors:  Hayato Iwase; Burcin Ekser; Vikas Satyananda; Jay Bhama; Hidetaka Hara; Mohamed Ezzelarab; Edwin Klein; Robert Wagner; Cassandra Long; Jnanesh Thacker; Jiang Li; Hao Zhou; Maolin Jiang; Santosh Nagaraju; Huidong Zhou; Massimiliano Veroux; Pietro Bajona; Martin Wijkstrom; Yi Wang; Carol Phelps; Nikolai Klymiuk; Eckhard Wolf; David Ayares; David K C Cooper
Journal:  Xenotransplantation       Date:  2015-04-03       Impact factor: 3.907

7.  Up to 9-day survival and control of thrombocytopenia following alpha1,3-galactosyl transferase knockout swine liver xenotransplantation in baboons.

Authors:  Karen Kim; Christian Schuetz; Nahel Elias; Gregory R Veillette; Isaac Wamala; Manish Varma; R Neal Smith; Simon C Robson; A Benedict Cosimi; David H Sachs; Martin Hertl
Journal:  Xenotransplantation       Date:  2012 Jul-Aug       Impact factor: 3.907

8.  The Effects of Exogenous Administration of Human Coagulation Factors Following Pig-to-Baboon Liver Xenotransplantation.

Authors:  N Navarro-Alvarez; J A Shah; A Zhu; J Ligocka; H Yeh; N Elias; I Rosales; R Colvin; A B Cosimi; J F Markmann; M Hertl; D H Sachs; P A Vagefi
Journal:  Am J Transplant       Date:  2016-02-05       Impact factor: 8.086

Review 9.  Achieving tolerance in pig-to-primate xenotransplantation: reality or fantasy.

Authors:  David H Sachs; Megan Sykes; Kazuhiko Yamada
Journal:  Transpl Immunol       Date:  2008-12-06       Impact factor: 1.708

Review 10.  Immunobiology of liver xenotransplantation.

Authors:  Burcin Ekser; Christopher Burlak; Joshua P Waldman; Andrew J Lutz; Leela L Paris; Massimiliano Veroux; Simon C Robson; Michael A Rees; David Ayares; Bruno Gridelli; A Joseph Tector; David Kc Cooper
Journal:  Expert Rev Clin Immunol       Date:  2012-09       Impact factor: 4.473

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.